Literature DB >> 28406849

Current Management Practices in Ménière's Disease.

Joseph W Clyde1, Benjamin S Oberman, Huseyin Isildak.   

Abstract

OBJECTIVE: To evaluate current trends in managing Ménière's disease (MD) by both general otolaryngologists and otologists/neurotologists and discuss treatment modalities. STUDY
DESIGN: Cross-sectional study.
SETTING: Survey of physicians. SUBJECTS AND METHODS: An electronic questionnaire was disseminated to all members of American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS).
RESULTS: Eight hundred and sixty members replied for a response rate of 14.5% for generalists and 35% for neurotologists. Thirty-nine percent of respondents think that diet and lifestyle changes are effective in controlling symptoms in more than 50% of their MD patients. Overall, 72.8% of respondents used hydrochlorothiazide/triamterene (HCTZ/TAT) "often" or "always" with neurotologists using HCTZ/TAT more often than generalists (p < 0.001). Half of neurotologists used IT steroids "often" or "always," compared with only 10% of generalists (p < 0.001). Endolymphatic sac procedures are the most common surgeries and are used more often by neurotologists than by generalists (p < 0.001). The Medtronic Meniett device is used more by neurotologists (p < 0.001) but it is not commonly used overall (69.2% "never" use).
CONCLUSION: Many options are available for the treatment of MD. Neurotologists tend to use a wider variety of medications in their treatment protocols than generalists. Neurotologists tend to perform surgical interventions more frequently than generalists. Our evidence shows significant heterogeneity for treatment of Ménière's disease among otolaryngologists. A guideline that outlines appropriate therapeutic options, dosing, and treatment escalation is warranted.

Entities:  

Mesh:

Year:  2017        PMID: 28406849     DOI: 10.1097/MAO.0000000000001421

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  Therapeutic strategies in the treatment of Menière's disease: the Italian experience.

Authors:  Nicola Quaranta; P Picciotti; G Porro; B Sterlicchio; G Danesi; P Petrone; Giacinto Asprella Libonati
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-11       Impact factor: 2.503

2.  Dexamethasone does not affect endolymphatic hydrops (EH) in patients with Meniere's disease within 24 h, and intratympanic administration of gadolinium plus dexamethasone simplifies high-quality imaging of EH using a novel protocol of 7 min.

Authors:  Jing Zou; Zikai Zhao; Hongbin Li; Guoping Zhang; Qing Zhang; Jianping Lu; Ilmari Pyykkö
Journal:  J Otol       Date:  2022-03-04

3.  Simultaneous labyrinthectomy and cochlear implantation in unilateral meniere's disease.

Authors:  Elizabeth Perkins; Meredith Rooth; Margaret Dillon; Kevin Brown
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-05-14

4.  Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study.

Authors:  Kenneth S Maxwell; James M Robinson; Ines Hoffmann; Huiying J Hou; Grant Searchfield; David M Baguley; Gordon McMurry; Fabrice Piu; Jeffery J Anderson
Journal:  Otol Neurotol       Date:  2021-12-01       Impact factor: 2.619

5.  Gentamicin delivery to the inner ear: Does endolymphatic hydrops matter?

Authors:  Pedro Marques; Maoli Duan; Nicolas Perez-Fernandez; Jorge Spratley
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.